DGIdb - GLESATINIB Drug Record

GLESATINIB chembl:CHEMBL3989914 Antineoplastic

Alternate Names:

MGCD265
MG90265
MGCD-265
GLESATINIB
MG90265X
MG90265GLY
MG-90265
MG-90265X
MG90265H9

Drug Info:

FDA Approval	not approved
Drug Class	Small molecule
Drug Indications	antineoplastic agent
Pharmaceutical Developer	MethylGene
Source Reported Drug Name(s)	MGCD265
Drug Class	MET Inhibitor
Drug Class	Kinase Inhibitors

(3 More Sources)

Publications:

Choi et al., 2004, Molecular mechanisms of heptaplatin effective against cisplatin-resistant cancer cell lines: less involvement of metallothionein., Cancer Cell Int.
Bahcall et al., 2016, Acquired METD1228V Mutation and Resistance to MET Inhibition in Lung Cancer., Cancer Discov
Engstrom et al., 2017, Glesatinib Exhibits Antitumor Activity in Lung Cancer Models and Patients Harboring MET Exon 14 Mutations and Overcomes Mutation-Mediated Resistance to Type I MET Inhibitors in Nonclinical Models., Clin. Cancer Res.

GLESATINIB TEK

Interaction Score: 0.91

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Novel drug target Novel Target

Trial Name MGCD265

Notes

PMIDs:
None found

Sources:
TALC TdgClinicalTrial
GLESATINIB MST1R

Interaction Score: 0.64

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Notes

Trial Name MGCD265

Novel drug target Novel Target

PMIDs:
None found

Sources:
TALC TdgClinicalTrial
GLESATINIB MET

Interaction Score: 0.59

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Notes

Reported Cancer Type Lung

Trial Name MGCD265

PMIDs:
15494073 27694386 28765324

Sources:
TALC MyCancerGenome TdgClinicalTrial JAX-CKB CancerCommons
GLESATINIB AXL

Interaction Score: 0.31

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
TTD
GLESATINIB FLT1

Interaction Score: 0.29

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Notes

Trial Name MGCD265

Novel drug target Established target

PMIDs:
None found

Sources:
TALC MyCancerGenome TdgClinicalTrial
GLESATINIB FLT4

Interaction Score: 0.28

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Notes

Novel drug target Established target

Trial Name MGCD265

PMIDs:
None found

Sources:
TALC MyCancerGenome TdgClinicalTrial
GLESATINIB KDR

Interaction Score: 0.18

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Notes

Trial Name MGCD265

Novel drug target Established target

PMIDs:
None found

Sources:
TALC MyCancerGenome TdgClinicalTrial
GLESATINIB EGFR

Interaction Score: 0.05

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy MGCD265 + Erlotinib

Indication/Tumor Type non-small cell lung carcinoma

Response Type predicted – sensitive

PMIDs:
None found

Sources:
JAX-CKB

CancerCommons: MGCD265
- Version: 25-July-2013
Alternate Names:

MGCD265 PubChem Drug Name

24901704 PubChem Drug ID

MGCD265 Drug Trade Name

Drug Info:

Drug Class MET Inhibitor

Source Reported Drug Name(s) MGCD265

Pharmaceutical Developer MethylGene

Publications:
MyCancerGenome: MGCD265
- Version: 20-Jun-2017
Alternate Names:

MGCD265 Development Name

Drug Info:

Drug Class Kinase Inhibitors

Publications:
TdgClinicalTrial: MGCD265
- Version: January-2014
Alternate Names:

Drug Info:

Drug Indications antineoplastic agent

Drug Class Small molecule

FDA Approval not approved

Publications:

JAX-CKB: MGCD265

Version: 27-September-2017

Alternate Names:

Drug Info:

Publications:

Bahcall et al., 2016, Acquired METD1228V Mutation and Resistance to MET Inhibition in Lung Cancer., Cancer Discov

Engstrom et al., 2017, Glesatinib Exhibits Antitumor Activity in Lung Cancer Models and Patients Harboring MET Exon 14 Mutations and Overcomes Mutation-Mediated Resistance to Type I MET Inhibitors in Nonclinical Models., Clin. Cancer Res.

Choi et al., 2004, Molecular mechanisms of heptaplatin effective against cisplatin-resistant cancer cell lines: less involvement of metallothionein., Cancer Cell Int.

TTD: MGCD265
- Version: 2020.06.01
Alternate Names:

D08FDX TTD Drug ID

Drug Info:

Publications:
TALC: MGCD265
- Version: 12-May-2016
Alternate Names:

MGCD265 Primary Drug Name

MGCD265 Drug Synonym

Drug Info:

Publications:
ChemblDrugs: chembl:CHEMBL3989914
- Version: ChEMBL_27
Alternate Names:

Drug Info:

Publications:

combination therapy	MGCD265 + Erlotinib
Indication/Tumor Type	non-small cell lung carcinoma
Response Type	predicted – sensitive

MGCD265	PubChem Drug Name
24901704	PubChem Drug ID
MGCD265	Drug Trade Name

Novel drug target	Novel Target
Trial Name	MGCD265
Notes

Notes
Trial Name	MGCD265
Novel drug target	Novel Target

Notes
Trial Name	MGCD265
Novel drug target	Established target

Notes
Novel drug target	Established target
Trial Name	MGCD265

GLESATINIB Drug Record

GLESATINIB chembl:CHEMBL3989914 Antineoplastic

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Novel drug target Novel Target Trial Name MGCD265 Notes

PMIDs: None found

Sources: TALC TdgClinicalTrial

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Notes Trial Name MGCD265 Novel drug target Novel Target

PMIDs: None found

Sources: TALC TdgClinicalTrial

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Notes Reported Cancer Type Lung Trial Name MGCD265

PMIDs: 15494073 27694386 28765324

Sources: TALC MyCancerGenome TdgClinicalTrial JAX-CKB CancerCommons

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: TTD

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Notes Trial Name MGCD265 Novel drug target Established target

PMIDs: None found

Sources: TALC MyCancerGenome TdgClinicalTrial

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Notes Novel drug target Established target Trial Name MGCD265

PMIDs: None found

Sources: TALC MyCancerGenome TdgClinicalTrial

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Notes Trial Name MGCD265 Novel drug target Established target

PMIDs: None found

Sources: TALC MyCancerGenome TdgClinicalTrial

Interaction Types & Directionality: n/a

Interaction Info: combination therapy MGCD265 + Erlotinib Indication/Tumor Type non-small cell lung carcinoma Response Type predicted – sensitive

PMIDs: None found

Sources: JAX-CKB

CancerCommons: MGCD265

Alternate Names: MGCD265 PubChem Drug Name 24901704 PubChem Drug ID MGCD265 Drug Trade Name

Drug Info: Drug Class MET Inhibitor Source Reported Drug Name(s) MGCD265 Pharmaceutical Developer MethylGene

Publications:

MyCancerGenome: MGCD265

Alternate Names: MGCD265 Development Name

Drug Info: Drug Class Kinase Inhibitors

Publications:

TdgClinicalTrial: MGCD265

Alternate Names:

Drug Info: Drug Indications antineoplastic agent Drug Class Small molecule FDA Approval not approved

Publications:

JAX-CKB: MGCD265

Alternate Names:

Drug Info:

TTD: MGCD265

Alternate Names: D08FDX TTD Drug ID

Drug Info:

Publications:

TALC: MGCD265

Alternate Names: MGCD265 Primary Drug Name MGCD265 Drug Synonym

Drug Info:

Publications:

ChemblDrugs: chembl:CHEMBL3989914

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Novel drug target Novel Target

Trial Name MGCD265

Notes

PMIDs:
None found

Sources:
TALC TdgClinicalTrial

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Notes

Trial Name MGCD265

Novel drug target Novel Target

PMIDs:
None found

Sources:
TALC TdgClinicalTrial

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Notes

Reported Cancer Type Lung

Trial Name MGCD265

PMIDs:
15494073 27694386 28765324

Sources:
TALC MyCancerGenome TdgClinicalTrial JAX-CKB CancerCommons

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
TTD

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Notes

Trial Name MGCD265

Novel drug target Established target

PMIDs:
None found

Sources:
TALC MyCancerGenome TdgClinicalTrial

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Notes

Novel drug target Established target

Trial Name MGCD265

PMIDs:
None found

Sources:
TALC MyCancerGenome TdgClinicalTrial

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Notes

Trial Name MGCD265

Novel drug target Established target

PMIDs:
None found

Sources:
TALC MyCancerGenome TdgClinicalTrial

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy MGCD265 + Erlotinib

Indication/Tumor Type non-small cell lung carcinoma

Response Type predicted – sensitive

PMIDs:
None found

Sources:
JAX-CKB

Alternate Names:

MGCD265 PubChem Drug Name

24901704 PubChem Drug ID

MGCD265 Drug Trade Name

Drug Info:

Drug Class MET Inhibitor

Source Reported Drug Name(s) MGCD265

Pharmaceutical Developer MethylGene

Alternate Names:

MGCD265 Development Name

Drug Info:

Drug Class Kinase Inhibitors

Drug Info:

Drug Indications antineoplastic agent

Drug Class Small molecule

FDA Approval not approved

Alternate Names:

D08FDX TTD Drug ID

Alternate Names:

MGCD265 Primary Drug Name

MGCD265 Drug Synonym